Back to overview

Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Procopio M. G., Laszlo C., Al Labban D., Kim D. E., Bordignon P., Jo S. H., Goruppi S., Menietti E., Ostano P., Ala U., Provero P., Hoetzenecker W., Neel V., Kilarski W. W., Swartz M. A., Brisken C., Lefort K., Dotto G. P.,
Project Cancer stromal cell genetic control
Show all

Original article (peer-reviewed)

Journal Nat Cell Biol
Volume (Issue) 17
Page(s) 1193 - 204
Title of proceedings Nat Cell Biol


Stromal fibroblast senescence has been linked to ageing-associated cancer risk. However, density and proliferation of cancer-associated fibroblasts (CAFs) are frequently increased. Loss or downmodulation of the Notch effector CSL (also known as RBP-Jkappa) in dermal fibroblasts is sufficient for CAF activation and ensuing keratinocyte-derived tumours. We report that CSL silencing induces senescence of primary fibroblasts from dermis, oral mucosa, breast and lung. CSL functions in these cells as a direct repressor of multiple senescence- and CAF-effector genes. It also physically interacts with p53, repressing its activity. CSL is downmodulated in stromal fibroblasts of premalignant skin actinic keratosis lesions and squamous cell carcinomas, whereas p53 expression and function are downmodulated only in the latter, with paracrine FGF signalling as the probable culprit. Concomitant loss of CSL and p53 overcomes fibroblast senescence, enhances expression of CAF effectors and promotes stromal and cancer cell expansion. The findings support a CAF activation-stromal co-evolution model under convergent CSL-p53 control.